|
|
|
|
|
|
|
|
|
|
abstract
Highlights
- •
- We carried out a survey to assess current opinions of Dutch gynecologists and medical oncologists regarding surgery in recurrent ovarian cancer
- •
- Most respondents were convinced of the benefit of secondary cytoreductive surgery and shared their opinion regarding diagnostic and therapeutic aspects
- •
- Gynecologists and medical oncologists differed in their opinion regarding the gain in both progression free as well as overall survival
Objective
Evidence
of randomized comparative clinical trials on surgery in recurrent
platinum-sensitive ovarian cancer is non-existing. Three randomized
phase 3 trials are ongoing. The aim of this study is to evaluate the
current opinion of Dutch gynecologists and medical oncologists awaiting
the results of these three trials.
Methods
A
16-item questionnaire was sent to all gynecologists (N = 124) and
medical oncologists (N = 195) with special interest in gynecologic
oncology in the Netherlands. The data were collected and analyzed using
descriptive statistics.
Results
In
total, 80 (65.0%) gynecologists and 67 (34.0%) medical oncologists
responded. Among the respondents, 11.3% and 26.9% were not convinced of
the benefit of secondary cytoreductive surgery, respectively. For most
gynecologists and medical oncologists completeness of primary surgery
(74.6% and 75.5%, respectively) and performance status (100% and 98%,
respectively) were important factors when considering surgery. For only
about 17.5% of all respondents diagnostic laparoscopy before surgery is a
prerequisite. Most respondents (81.7% and 87.8%, respectively) would
use platinum-based chemotherapy with paclitaxel as their agents of
choice after surgery. In general medical oncologists settle for a
smaller gain in both progression free as well as overall survival than
gynecologists.
Conclusions
Although
most gynecologists and medical oncologists are already convinced of the
usefulness of secondary cytoreductive surgery in certain patients, a
better understanding of the real advantages and disadvantages and
patient’s selection criteria for secondary cytoreductive surgery will be
achieved after the completion of three ongoing randomized controlled
trials (DESKTOP III, GOG 213 and the SOCceR).
Purchase $39.95
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.